Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 10,357 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Atopic Dermatitis
Interventions: omalizumab; Biological
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Immune Deficiency Disorder
Interventions: RI-002; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Cenntennial, Colorado • North Palm Beach, Florida • Atlanta, Georgia + 5 more

Conditions: Tourette's Disorder
Interventions: vigabatrin; Drug
Lead sponsor: Barbara J. Coffey; Other
Eligibility: 18 Years to 35 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: EaseVRx, Audio-only version of EaseVRx; Device · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Epidermolysis Bullosa
Interventions: allo-APZ2-OTS, Placebo; Drug
Lead sponsor: RHEACELL GmbH & Co. KG; Industry
Eligibility: 6 Months and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Minneapolis, Minnesota

Conditions: Fetal Alcohol Spectrum Disorders, Attention Deficit Hyperactivity Disorder
Interventions: Trigeminal Nerve Stimulation (TNS); Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 8 Years to 12 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease, Graft Versus Host Disease
Interventions: Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil; Drug · Procedure
Lead sponsor: Monica Bhatia; Other
Eligibility: 3 Years to 20 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Basal Cell Carcinoma
Interventions: Not listed
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Oakland, California

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: antitumor drug screening assay, chemotherapy, biological therapy; Other · Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
Interventions: Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 13 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Advanced Solid Tumor, Advanced Solid Malignancies
Interventions: PRJ1-3024; Drug
Lead sponsor: Zhuhai Yufan Biotechnologies Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • Cincinnati, Ohio + 3 more

Conditions: Degenerative Disc Disease (DDD), Instabilities, Trauma, Deformity
Interventions: VERTICALE® Cervical System; Device
Lead sponsor: Silony Medical GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation
Interventions: NAVA, CMV; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 24 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Providence, Rhode Island

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Valganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more

Conditions: Sickle Cell Disease
Interventions: Hydroxyurea; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 24 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
Interventions: 68Gallium DOTATATE, Radio-guided surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years to 99 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis
Interventions: decolonization; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 2 Months to 23 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Anemia, Sickle Cell, Transfusion Hemosiderosis
Interventions: deferasirox; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 14 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Down Syndrome
Interventions: Speech therapy addressing phonology and motor learning; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years to 16 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
Interventions: Not listed
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Seattle, Washington

Conditions: Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Interventions: ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Peoria, Arizona • La Mesa, California • Norcross, Georgia + 11 more

Conditions: Biliary Atresia
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 6 Months to 20 Years
Enrollment: 1,265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Search by objective public record fields.

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder

Home-Based Intervention for Chronic Pain in Adults With Sickle Cell Disease

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

PMCF Study to Evaluate the VERTICALE® Cervical System in Spine Surgery According to Its Intended Use.

NAVA vs. CMV Crossover in Severe BPD

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

Hydroxyurea and Transfusion

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease

Down Syndrome Speech Intelligibility Diagnostic Treatment Study

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Biliary Atresia Study in Infants and Children